AstraZeneca and Absci's AI Alliance in Cancer Antibody Research
AstraZeneca partners with AI firm Absci in a groundbreaking $247 million venture to develop advanced cancer-fighting antibodies, marking a significant stride in AI's integration with healthcare research.
![image YouQuan](https://image.coinlive.com/24x24/cryptotwits-static/e26a5ef5654a5ee4a42afc3949285878.jpeg)